NCT05483257View on ClinicalTrials.gov

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

226

Participants

Timeline

Start Date

March 14, 2018

Primary Completion Date

August 3, 2020

Study Completion Date

September 13, 2021

Conditions
Pancreatic Cancer Resectable
Interventions
DEVICE

Multigene panel for next-generation sequencing

HLA-I genotyping based on next-generation sequencing for prognosis evaluation

Trial Locations (1)

200025

Ruijin Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

GeneCast Biotechnology Co., Ltd.

INDUSTRY

lead

BAIYONG SHEN

OTHER

NCT05483257 - Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter